BioSpace News Archive

AB Science SA (Euronext - FR0010557264 - AB) today announces that the first authorizations have been received to initiate its phase 3 confirmatory study (AB21004) evaluating masitinib in patients with mild to moderate Alzheimer’s Disease (AD) from the French Medicine Agency (ANSM) together with AEMPS (Spain agency) and EOF (Greece agency).

Synergys Biotherapeutics, a preclinical stage biotherapeutics company developing Vasculogenic Mimicry (VM)-blocking antibody fusion drugs, announced today that it has been awarded a Phase I/Phase II Fast-Track grant from the National Cancer Institute under the auspices of the Small Business Innovation Research (SBIR) program of the National Institutes of Health.

The American Association of Clinical Endocrinology (AACE) issued an update to its Developing a Diabetes Mellitus Comprehensive Care Plan guideline, which included a grade A recommendation* for Bayer’s KERENDIA® (finerenone) for the management of patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).

Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company committed to improving health equity for seniors, today announced that it will report third quarter 2022 financial results after market close on Monday, November 7, 2022.

Atara Biotherapeutics, Inc. reported the grant of 8,000 restricted stock units of Atara’s common stock to one newly hired employee.

CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the third quarter 2022 after the market close on Wednesday, October 26, 2022.

AccuStem Sciences, Inc. announced that its 2022 annual meeting of stockholders on October 10, 2022 at 9:00 a.m. Eastern Time was convened and adjourned, without any business being conducted, due to lack of the required quorum.

Crinetics Pharmaceuticals, Inc. announced that on October 10, 2022, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 237,600 shares of its common stock to eleven new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan.

Translumina - a global developer and manufacturer of innovative cardiovascular medical devices, implants and access products - appointed Indranil Mukherjee as Group CEO and Armin Kiser as Managing Director and Chief Operating Officer for the company’s Europe operations.

Plexision, a biotechnology company, which provides personalized diagnostic testing services for organ transplant patients has completed development of a six-hour blood test to predict organ transplant rejection - PlexAPR™.